Epileptic activity arises from an imbalance in excitatory and inhibitory synaptic transmission. To determine if alterations in the metabolism of glutamate, the primary excitatory neurotransmitter, might contribute to epilepsy we directly and indirectly modified levels of glutamine, an immediate precursor of synaptically released glutamate, in the rat neocortical undercut model of hyperexcitability and epilepsy. We show that slices from injured cortex take up glutamine more readily than control slices, and an increased expression of the system A transporters SNAT1 and SNAT2 likely underlies this difference. We also examined the effect of exogenous glutamine on evoked and spontaneous activity and found that addition of physiological concentrations of glutamine to perfusate of slices isolated from injured cortex increased the incidence and decreased the refractory period of epileptiform potentials. By contrast, exogenous glutamine increased the amplitude of evoked potentials in normal cortex, but did not induce epileptiform potentials. Addition of physiological concentrations of glutamine to perfusate of slices isolated from injured cortex greatly increased abnormal spontaneous activity in the form of events resembling spreading depression, again while having no effect on slices from normal cortex. Interestingly, similar spreading depression like events were noted in control slices at supraphysiological levels of glutamine. In the undercut cortex addition of methylaminoisobutyric acid (MeAIB), an inhibitor of the system A glutamine transporters attenuated all physiological effects of added glutamine suggesting that uptake through these transporters is required for the effect of glutamine. Our findings support a role for glutamine transport through SNAT1 and/or SNAT2 in the maintenance of abnormal activity in this in vitro model of epileptogenesis and suggest that system A transport and glutamine metabolism are potential targets for pharmacological intervention in seizures and epilepsy.
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Introduction
An underlying imbalance between excitation and inhibition is thought to mediate seizure activity. It follows that alterations in metabolism of glutamate, the primary excitatory neurotransmitter, are likely to have marked effects on epileptiform activity. The most direct mechanism for the recycling of neurotransmitters is presynaptic reuptake followed by repackaging in synaptic vesicles (Krantz et al., 1999) , but presynaptic plasma membrane glutamate transporters are absent from the vast majority of excitatory neurons indicating that such a mechanism is not used for recycling synaptically released glutamate (Danbolt, 2001) . Instead, the glutamate backbone appears to transit through a glutamate-glutamine shuttle between neurons and glia. In this pathway, released glutamate is cleared from the synapse by high affinity excitatory amino acid transporters (EAATs) on the glial plasma membrane (Chaudhry et al., 2002a; Hamberger et al., 1979a; Laake et al., 1995) . The high level of expression of these transporters in the perisynaptic space, their high affinity and their ionic coupling leads to low resting levels of the glutamate in the cleft and minimizes the diffusion of the neurotransmitter (Chaudhry et al., 1995; Nicholls and Attwell, 1990; Zerangue and Kavanaugh, 1995; Zhou and Sutherland, 2004) . Once cleared from the synapse, glutamate is metabolized to glutamine by the glial-specific enzyme glutamine synthetase (GS). The glutamine is then released from glial cells and taken up by neurons where it is converted to glutamate through the activity of mitochondrial phosphate activated glutaminase (PAG) and repackaged into synaptic vesicles for rerelease. The relevance of this pathway in glutamate recycling is supported by marked reduction in synaptically released glutamate by inhibition of glutamine synthetase or glutaminase (Conti and Minelli, 1994; Rothstein and Tabakoff, 1984) . Unlike glutamate, glutamine does not appear to have specific neuronal receptors or to be directly involved in neuronal signaling. Indeed the glutamine concentration in the cerebrospinal fluid is several hundred millimolar (Fishman, 1992; Lerma et al., 1986) , many fold higher than any other amino acid, making for an ideal extracellular intermediate in the pathway.
Glutamine also plays a role in the metabolism of the primary inhibitory neurotransmitter, GABA. Although the majority of GABA is taken up by GABAergic neurons, approximately one- 
